In chimeric antigen receptor (CAR)-T cell therapy blood cells of cancer patients are modified to destroy their cancer cells. CAR-T cell therapy has already revolutionized the treatment of many leukemias, but there are still hurdles that need be overcome to unleash its therapeutic potential against solid cancers. Our earlier work has successfully addressed these challenges using a novel technology developed in our laboratory, namely sherpabodies, to improve the ability CAR-T cell to detect and attack cancer. In the project proposed here we plan to further document and highlight the advantages of this new technology by directly and systematically comparing it with the current state-of-the art CAR-T cell therapies in relevant experimental models. Such additional proof of concept will be important to better convey our message to the relevant stakeholders within and outside of the academic community to promote clinical translation and commercialization of these promising results. .

2025

2026